2025/04/24 M Ventures co-leads $18.7M Series A investment in ChEmpower ChEmpower raises $18.7M to advance semiconductor chip polishing technology
2025/04/15 Corvic AI Raises $12M in Seed Funding to Pioneer AI Cognitive Infrastructure for Enterprise Intelligence After Stealth Development, Corvic AI Unveils Data-Centric AI Cognitive Infrastructure for Mission-Critical Intelligence Across Complex Enterprise Data
2025/04/15 Corvic AI Raises $12M in Seed Funding to Pioneer AI Cognitive Infrastructure for Enterprise Intelligence
2025/03/12 Celestial AI Secures $250 Million Funding to Revolutionize AI Infrastructure with Its Photonic Fabric
2025/03/05 TRIMTECH Therapeutics raises $31M to advance targeted protein degradation for treatment of neurodegenerative diseases
2025/01/21 NovoLINC Secures Investments to Assist AI Computing with Groundbreaking Thermal Interface Technology
2025/01/16 Outrun Therapeutics expands leadership team with appointment of Matthew Fyfe as Chief Scientific Officer
2025/01/13 Ribometrix Strengthens Leadership by appointing William S. Marshall as CEO and Katie Warner as CSO
2024/12/04 Abselion raises £6.6 million led by M Ventures to bring disruptive at-line protein analyser, Amperia, to market
2024/11/19 Concerto Biosciences Announces First Participant Dosed with Live Biotherapeutic ENS-002 in Phase 1 Trial for Atopic Dermatitis
2024/11/19 Nouscom Completes Patient Enrollment of Randomized Phase 2 Study Evaluating NOUS-209, an Off-the-Shelf Neoantigen Immunotherapy, in dMMR/MSI Metastatic Colorectal Cancer
2024/10/29 Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates
2024/10/04 Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens
2024/09/19 PictorLabs Raises $30 Million in Series B Funding to Accelerate AI-Powered Virtual Staining Technology
2024/09/10 Formo bags $61 million in Series B funding - launches the world’s first animal-free cheese made with Koji Protein
2024/09/03 Scrona AG and Electroninks Announce Collaboration in Materials and Process Development for Advanced Semiconductor Packaging
2024/09/03 Electroninks Launches World-First Copper MOD Ink to Revolutionize Advanced Semiconductor Packaging
2024/08/07 Anjuna Raises $25M Funding to Fuel Momentum and Expand Confidential Computing Offerings for AI
2024/07/16 M Ventures Participates in Asceneuron's $ 100M Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases
2024/06/20 iOnctura announces EUR80 million Series B financing to progress pipeline through Phase II trials
2024/05/21 LabGenius raises £35 million led by M Ventures to further develop its ML-driven antibody discovery platform and progress a pipeline of assets towards the clinic
2024/04/11 Merck KGaA, Darmstadt, Germany’s Corporate Venture M Ventures Arm Backs Nucleai to Advance Its First-in-class Spatial AI Biomarker in Active Clinical Enrollment
2024/04/04 Biolinq Raises $58 Million to Advance Wearable Biosensors Through Pivotal Trial for Metabolic Health Using Precision Microsensor Technology
2024/03/06 Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases
2024/01/16 DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
2024/01/08 M Ventures portfolio company Calypso, a Merck KGaA, Darmstadt, Germany spin-out, enters into agreement to be acquired by Novartis
2023/11/15 M Ventures co-leads a €67.5 million oversubscribed Series C round for cancer immunotherapy company Nouscom
2023/10/18 CEGYR leads as first fertility clinic globally to use Future Fertility’s AI-powered egg assessment on all cycles
2022/12/22 PictorLabs Launches with More Than $18.8 Million to Advance Transformative Virtual Staining
2022/12/20 IOnctura Awarded EUR17.5 Million Funding From The EIC Accelerator For Clinical Development Of Novel Pancreatic Cancer Therapy
2022/12/15 Calypso Biotech announces first patient with Eosinophilic Esophagitis dosed in antiInterleukin-15 (IL-15) monoclonal antibody CALY-002 Phase 1a/b Trial, and animal proof of concept data in Atopic Dermatitis
2022/12/08 IOnctura Initiates Phase Ib Pancreatic Cancer Trial Of Next-Generation Autotaxin Inhibitor IOA-289
2022/11/30 Electroninks Partners with Citrine Informatics to Develop Enhanced Silver Ink Using AI-Assisted R&D
2022/11/09 Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results
2022/10/18 Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering
2022/10/06 Theolytics presents CAF-targeting therapy for stromal rich tumours, and strengthens leadership team
2022/09/12 Fierce Biotech names STORM Therapeutics as one of its “Fierce 15” Biotech Companies of 2022
2022/08/09 Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results
2022/06/09 Metalenz and STMicroelectronics Deliver World’s First Optical Metasurface Technology for Consumer Electronics Devices
2022/05/31 Altoida Appoints Neuroscience Pioneer Dr. Antontella Santuccione Chadha as Chief Medical Officer
2022/05/31 Theolytics' £1M project with InnovateUK to develop a novel therapy for multiple myeloma patients
2022/04/28 Abbvie and Plexium Enter into Multi-target Strategic Collaboration to Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions
2022/04/28 Electroninks Announces Production-Scale Availability of Full Suite of Metal Complex Conductive Ink Solutions
2022/04/15 SynSense steps into the field of smart cockpits by initiating a technological exploration with BMW
2022/04/12 DNA Script Launches Early Access Program for Latest Advancements to the SYNTAX Platform and Enzymatic DNA Synthesis Technology
2022/04/08 iOnctura data at AACR demonstrates unique mechanism of action for clinical stage autotaxin inhibitor IOA-289
2022/04/05 DNA Script Partners with Asia-Pacific Distributors as Part of Global Expansion to Meet Demand for Same-day Enzymatic DNA Synthesis
2022/03/30 Altoida upsizes its Series A Round to $20.3M to Advance Its First in Class AI-Powered Neurocognitive Assessment Platform
2022/03/09 iOnctura To Present Preclinical Data On Its Clinical Stage Autotaxin Inhibitor, IOA-289, At AACR
2022/03/08 Akili Named to Fast Company’s Annual List of the World’s 50 Most Innovative Companies for 2022
2022/03/08 DNA Script Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2022
2022/02/23 Plexium Announces $102m Financing to Advance Pipeline of Targeted Protein Degradation Therapies and Technology Platform
2022/02/04 Celestial AI Raises $56 Million Series A to Disrupt the Artificial Intelligence Chipset Industry with Novel Photonic-Electronic Technology Platform
2022/02/02 Amgen and Plexium Announce Multi-year, Drug Discovery Collaboration to Identify Novel Targeted Protein Degradation Therapies
2022/01/26 Akili to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I
2022/01/20 Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors
2022/01/06 Future Fertility Raises Series A to Progress First-In-Class AI-Enabled Fertility Solutions to Improve IVF Outcomes
2021/12/09 Anavo Therapeutics Announces the Appointment of Charles McDermott as Chairman of the Board
2021/12/08 Merck KGaA, Darmstadt, Germany KGaA, Darmstadt, Germany, Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million
2021/10/26 DNA Script Raises $165M in Oversubscribed Series C Financing to Accelerate Commercialization of Enzymatic DNA Printing Platform
2021/10/18 Xilio Therapeutics Announces FDA Clearance of Investigational New Drug Application for XTX202 for the Treatment of Solid Tumors
2021/09/16 Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX101 for the Treatment of Patients with Solid Tumors
2021/08/05 Altoida Awarded FDA Breakthrough Designation for Development of World’s First Precision Neurology Device for Prediction of Alzheimer's Disease
2021/07/19 NanoSyrinx announces oversubscribed £6.2M Seed+ funding round to develop its novel biologic delivery platform
2021/06/24 Anavo Therapeutics Strengthens Scientific Advisory Board with Industry-Leading Drug Discovery Experts in Oncology
2021/05/25 Xilio Therapeutics Announces Clinical Trial Collaboration With Merck KGaA, Darmstadt, Germany on Anti-CTLA-4 Monoclonal Antibody Program
2021/05/17 Soteria Biotherapeutics Launches with $42 Million Series A Financing Led by Roche Venture Fund and 5AM Ventures
2021/04/22 Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators
2021/03/08 STORM Therapeutics Expands Scientific Advisory Board with the Appointment of Professor Tsutomu Suzuki
2021/03/03 FORENDO PHARMA SUCCESSFULLY COMPLETES PHASE 1 STUDIES OF FOR-6219 IN ENDOMETRIOSIS, AIMING TO ADVANCE PROGRAM INTO PHASE 2 CLINICAL STUDIES
2021/02/24 Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline
2021/02/11 Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients
2020/12/03 Merck KGaA, Darmstadt, Germany KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology
2020/11/17 Ferroelectric Memory GmbH (FMC) Raises $20 Million to Accelerate Next-Generation Memory for AI, IoT, Edge Computing, and Data Center Applications
2020/11/16 Calypso Biotech announces successful dosing of first Phase 1 cohort with anti-Interleukin-15 (IL-15) monoclonal antibody CALY-002 for the treatment of Autoimmune Diseases
2020/11/12 Xilio Therapeutics Presents Promising Preclinical Tumor-Selective Efficacy and Safety Data for XTX201 (IL-2) and XTX101 (anti-CTLA-4) at SITC
2020/09/30 Synthetic Biology start up NanoSyrinx secures capital to develop its fully customisable platform for intra-cellular engineering
2020/07/08 Sonde Health Launches New Voice-Enabled Health Screening Tool to Help Employers Return to Work During the Global Pandemic
2020/06/15 Akili Announces FDA Clearance of EndeavorRx™ for Children with ADHD, the First Prescription Treatment Delivered Through a Video Game
2020/04/22 Akili Announces ENDEAVORTM Digital Attention Treatment is Now Available for Children with Attention Deficit Hyperactivity Disorder (ADHD) under FDA’s COVID-19 Enforcement Discretion Guidance
2020/01/17 Neurable raises $6 million to develop brain-sensing consumer devices, beginning with headphones
2019/12/20 Berlin-based startup Legendairy Foods has raised €4M to develop cheese and other dairy products that have the same composition as milk but are not derived from animals
2019/11/21 Immunitas Therapeutics Launches with $39 Million to Advance Lead Programs to Human Efficacy Studies Based on a Unique Immunology-Focused Drug Development Platform
2019/09/24 Artios Pharma appoints Tania Dimitrova as Chief Business Officer and expands presence in the United States
2019/06/20 John Conway, Former Head of Data Sciences and AI at AstraZeneca, Joins Riffyn as Chief Commercial Officer
2019/06/01 Altoida raises $6.3m Series A to Predict Alzheimer’s Disease Risk Using Artificial Intelligence, Machine Learning and Augmented Reality
2019/05/14 GE Healthcare and Indi Molecular to collaborate on diagnostic tool for clinical management of immunotherapy patients
2019/04/11 Sonde Completes $16 Million Series A Financing Round to Advance Vocal Biomarker Technology
2019/01/16 ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors
2018/11/13 Ribometrix Announces $30 Million Series A Funding to Advance Pipeline of RNA-Targeting Small Molecule Therapies
2018/10/26 Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development
2018/10/03 Rewind Therapeutics appoints leading neuroscience drug developer Ian J. Reynolds as Chief Executive Officer
2018/09/20 VAXIMM Announces Regional Development and Commercialization Agreement with China Medical System Holdings
2018/09/10 MACROPHAGE PHARMA ANNOUNCES APPOINTMENT OF LEADING INTERNATIONAL SCIENTIFIC ADVISORY BOARD
2018/08/23 ApoGen Biotechnologies Expands Series A Financing to $11 Million and Enhances Leadership Team
2018/07/18 Asceneuron’s tau modifier ASN120290 receives Orphan Drug Designation for progressive supranuclear palsy from the FDA
2018/07/04 Forendo Pharma initiates phase I study for potential new, targeted treatment for endometriosis
2018/05/14 Synaffix Further Strengthens Its Scientific Advisory Board with the Addition of John Lambert PhD, Former CSO of ImmunoGen
2018/05/09 Akili Completes $55 Million Financing to Advance Company’s Digital Medicine Platform and Product Pipeline Aimed at Treating Cognitive Dysfunction
2018/05/07 Medisafe Demonstrates Double-Digit Impact on Medication Adherence in Hypertension Patients
2018/03/19 FORENDO PHARMA RECEIVES €3 MILLION LOAN FROM BUSINESS FINLAND TO DEVELOP NOVEL TREATMENTS FOR ENDOMETRIOSIS
2018/03/16 Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson's disease
2018/03/05 Artios exercises option to in-license potential first-in-class nuclease development programme
2018/01/29 STORM Therapeutics Appoints Distinguished Professor and Nobel Prize Winner Professor Thomas Cech as Scientific Advisor
2017/12/12 aveni® S.A. Extends Copper Interconnects to 5nm and Below for BEOL Integration Using Innovative Electroplating Chemistry
2017/11/29 Synaffix Commands IP Space of Glycan-Conjugated ADCs Through Major Expansion of Granted Patent Portfolio
2017/11/27 STORM THERAPEUTICS ANNOUNCES PUBLICATION IN NATURE ON RNA EPIGENETICS BY FOUNDER PROFESSOR TONY KOUZARIDES
2017/11/13 The IQVIA Institute for Human Data Science's Latest Report Names Medisafe as The Top Free & Publicly Available App for Medication Management
2017/11/06 STORM Therapeutics Strengthens Board with Appointment of Professor Paul Workman, President and CEO of The Institute of Cancer Research
2017/11/02 Two Global Leaders in Technology and Healthcare Join List of Venture Capitalists Investing in Wiliot to Scale IoT with Battery-Free Bluetooth
2017/10/11 ADC Therapeutics Triggers Second Target-Specific License to Synaffix ADC Platform under Existing Agreement
2017/10/10 FORENDO PHARMA NOMINATES WORLD CLASS SCIENTIFIC ADVISORY BOARD AND ELECTS PROFESSOR LINDA GIUDICE AS THE CHAIRPERSON
2017/09/15 Artios Pharma wins Life Science Young Company of the Year and UK Private Finance Raise at the Biotech and Money Annual Awards 2017
2017/09/13 VAXIMM Receives Orphan Designation for the European Union and the US for Oral T-cell Immunotherapy VXM01 to Treat Glioma
2017/09/12 M Ventures participates in DNA Script' Successful Series A Fundraising of €11 M to Advance Development of its DNA Synthesis Technology
2017/08/18 ALCAN, a German Smart Antenna Start-up, Raises EUR 7.5 million to Manufacture Flat Panel Phased Array Antennas
2017/06/29 ObsEva Announces Presentations Related to its Assisted Reproductive Technology (ART) and Pre-term labor (PTL) Development Programs at ESHRE 2017 Annual Meeting
2017/06/07 ObsEva SA Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back Therapy
2017/05/18 VAXIMM Announces Data from Phase I Trial in Glioblastoma with Oral T-cell Immunotherapy VXM01 to be Presented at ASCO 2017 Annual Meeting
2017/05/16 Synaffix Secures End-to-End Patent Protection of Its ADC Technology Platform as Its HydraSpace™ Patent Grants in the United States
2017/05/11 ObsEva SA to Hold First Quarter 2017 Financial Results and Business Update Call on Thursday, May 18, 2017
2017/05/09 VAXIMM Announces Collaboration with Merck KGaA, Darmstadt, Germany KGaA, Darmstadt, Germany, and Pfizer to Evaluate Combination of VXM01 with Avelumab in Glioblastoma and Colorectal Cancer in Phase I/II Clinical Studies
2017/03/30 VAXIMM to present preclinical data on three novel oral T-cell immunotherapies at AACR Annual Meeting 2017
2017/02/20 New Data Demonstrate Significant Expansion of Therapeutic Index vs Cysteine-Engineered ADCs
2017/02/08 Prexton Therapeutics Series B financing round raises €29 million ($31M) to advance its novel Parkinson’s therapeutic
2017/01/13 ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor
2016/11/02 Artios Pharma Ltd: Strengthened Management Team with the Appointment of Dr Simon Boulton as Vice President Science Strategy
2016/10/24 ObsEva Announces Results of the IMPLANT Phase 2 Trial of OBE001 (nolasiban) for the Improvement of Pregnancy and Live Birth Rates Following IVF/ICSI
2016/10/12 ObsEva Randomizes First Patient in Phase 2b EDELWEISS Study of OBE2109 for the Treatment of Endometriosis
2016/09/21 Artios Pharma Company Launch and Fundraising of $33.2 Million to Focus on Novel DNA Damage Response (DDR) Cancer Therapies
2016/07/20 Akili Adds Amgen Ventures and M Ventures* to Series B Financing, Increasing Round to $42.4 Million
2016/07/20 Synaffix Achieves Significantly Improved Therapeutic Index Compared to Both FDA-Approved ADCs and Expands Its Scientific Advisory Board
2016/06/28 Storm Therapeutics raises £12 million Series ‘A’ funding to target enzymes that modify RNA to generate novel cancer therapeutics
2016/01/11 F-star Enters into Collaborative Discovery & Development Agreement with AbbVie for Bispecific Antibodies in Immuno-oncology
2016/01/04 Padlock Therapeutics Creates West Coast Operations Appointing Scientific Co-founder Kerri Mowen, Ph.D., as Director of Biology Based in San Diego
2015/05/28 Raze Therapeutics Announces Addition of Robert Copeland, PhD, to Scientific Advisory Board
2015/04/28 Padlock Therapeutics Assembles Scientific Advisory Board with World Leaders in PAD Enzyme Biology and Autoimmune Disease
2015/04/09 Alzheimer's Drug Discovery Foundation awarded a USD 325,000 grant to support the development of Asceneuron's tau modulators
2015/04/08 In new Nature paper, Raze Therapeutics co-founder David Sabatini discovers role for 1C metabolism in glioblastoma
2015/04/08 Padlock Therapeutics Initiates Collaborations with Three Leading Research Partners on the Biology of PAD Enzymes
2015/02/26 ObsEva Reports Positive Phase 1 Results for the First Orally Active Oxytocin Antagonist OBE001 to Treat Preterm Labour
2015/01/07 Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration
2015/01/07 Raze Therapeutics Announces Addition of Julian Adams, PhD, George Q. Daley, MD, PhD, and Karen Vousden, PhD, to Scientific Advisory Board